Shire Aims for Market Leadership in Rare Diseases with US$32 B Baxalta Acquisition
By Heather Cartwright, Rohit Khera & Jasmine Kalsi
Pharma Deals Review: Vol 2016 Issue 1 (Table of Contents)
Published: 27 Jan-2016
DOI: 10.3833/pdr.v2016.i1.2140 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Shire has emerged victorious in its 6-month quest to acquire haemophilia specialist Baxalta with a cash-plus-stock deal worth approximately US$32 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS